Arcutis Biotherapeutics Shares Rise Premarket As FDA OKs Zoryve in Young Children
October 06 2023 - 7:52AM
Dow Jones News
By Colin Kellaher
Shares of Arcutis Biotherapeutics jumped in premarket trading
Friday after the biopharmaceutical company won Food and Drug
Administration expanded approval of its Zoryve cream for the
topical treatment of plaque psoriasis in children ages 6 to 11.
Arcutis shares, which closed Thursday at all-time low of $4.43,
were recently up 9.5% to $4.85 in premarket trading. The stock is
down about 70% for the year through Thursday.
The Westlake Village, Calif., company said the approval gives
children a steroid-free topical treatment for the most common form
of the skin disease psoriasis, including in intertriginous areas,
or skin folds.
The FDA last year approved Zoryve for the topical treatment of
plaque psoriasis in patients 12 and older and is reviewing the
cream for the treatment of seborrheic dermatitis in individuals age
9 and up, with a target action date of Dec. 16.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 06, 2023 08:37 ET (12:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From May 2023 to May 2024
